Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...5354555657585960616263...123124»
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Updated efficacy and safety of lenvatinib (LEN) + pembrolizumab (pembro) vs treatment of physician's choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775 (7.3.G - Grenoble Auditorium) -  Jul 25, 2022 - Abstract #ESMO2022ESMO_1761;    
    P3
    Editorial acknowledgement Medical writing support was provided by Irene Minkina, PhD, of Oxford PharmaGenesis Inc., Newtown, PA, USA, with funding by Eisai Inc., Nutley, NJ, USA, and Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA...Methods Pts with aEC and 1 prior platinum-based chemotherapy regimen (up to 2 if 1 was given in the neoadjuvant/adjuvant setting) were randomized (1:1) to receive LEN 20 mg orally QD + pembro 200 mg IV Q3W or TPC (doxorubicin at 60 mg/m 2 IV Q3W or paclitaxel at 80 mg/m 2 IV QW [3 wks on; 1 wk off])...Safety was generally consistent with the primary analysis and previous studies. Table: 525MO ORR, objective response rate; OS, overall survival; PFS, progression-free survival.
  • ||||||||||  Review, Journal:  Recent Advances in Systemic Therapy for Hepatocellular Carcinoma. (Pubmed Central) -  Jul 23, 2022   
    Most recently, the combination of atezolizumab plus bevacizumab was superior to front-line sorafenib. These results have radically changed the treatment landscape for patients with advanced hepatocellular carcinoma.
  • ||||||||||  lenvatinib / Generic mfg.
    Clinical, Journal, Real-world evidence, PD(L)-1 Biomarker, IO biomarker:  A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer. (Pubmed Central) -  Jul 23, 2022   
    Among the selected populations of patients with initial PD-L1-positive uHCC, pembrolizumab-lenvatinib-TACE sequential therapy may have promising antitumour activity, with an acceptable conversion rate and a well-characterized safety profile. Anti-PD-1 antibodies plus lenvatinib represent an effective and tolerable therapy for patients with advanced gallbladder cancer.
  • ||||||||||  Caprelsa (vandetanib) / Sanofi
    Review, Journal:  Daily Management of Patients on Multikinase Inhibitors' Treatment. (Pubmed Central) -  Jul 23, 2022   
    The follow-up visits should take place at monthly intervals until the sixth month and then every 1-2 months until the completion of the first year of treatment. The flow chart followed at our tertiary center is reported in the present review as a real-life-based example for the follow-up of patients with advanced TC on MKI treatment.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open, IO biomarker:  Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer (clinicaltrials.gov) -  Jul 20, 2022   
    P2,  N=31, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open, Trial completion date, Trial primary completion date, Metastases:  Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations (clinicaltrials.gov) -  Jul 20, 2022   
    P2,  N=30, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: Oct 2022 --> Oct 2024 | Trial primary completion date: May 2022 --> Oct 2023
  • ||||||||||  Stivarga (regorafenib) / Bayer, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Preclinical, Journal:  Comparative Response of HCC Cells to TKIs: Modified in vitro Testing and Descriptive Expression Analysis. (Pubmed Central) -  Jul 20, 2022   
    To this aim, the sensitivity of nine HCC cell lines to sorafenib, lenvatinib, regorafenib, and cabozantinib was evaluated by a prolonged treatment scheme to determine their respective growth rate inhibition concentrations (GR)...Subgroup analysis of TKI effectiveness showed distinct transcriptomic profiles and signaling pathways associated with responsiveness. This prompts more extensive studies to explore and validate pharmacogenomic and transcriptomic strategies for a personalized treatment approach, particularly after the failure of CPI treatment.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date, Metastases:  Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer (clinicaltrials.gov) -  Jul 19, 2022   
    P2,  N=25, Not yet recruiting, 
    In summary, our results demonstrate that a ZNF143-FBXO9-FBXW7 signaling regulatory axis may be involved in tumor progression in HCC, and suggest that FBXO9 could be a potential biomarker and therapeutic target for HCC. Trial completion date: Aug 2022 --> Aug 2023 | Trial primary completion date: Aug 2022 --> Aug 2023
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Journal:  Emerging drugs for the treatment of radioactive iodine refractory papillary thyroid cancer. (Pubmed Central) -  Jul 15, 2022   
    In patients with a targetable abnormality, specific inhibitors, might be used as first line treatment and lenvatinib as second line or vice-versa. Further studies are needed, based on documented genomic and immunologic characteristics of the tumor to assess the potential role of combination and redifferentiation therapy.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Retrospective data, Review, Journal:  Pembrolizumab in advanced renal cell carcinoma: a meta-analysis providing level 1a evidence. (Pubmed Central) -  Jul 15, 2022   
    Pembrolizumab-lenvatinib combination gave a marginal benefit in terms of OS, PFS and DoR relative to pembrolizumab-axitinib group. By relying on individual survival data, we provided a level-1a evidence supporting the use of pembrolizumab plus TKI for first-line aRCC treatment.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date, IO biomarker:  NeoPele: A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma (clinicaltrials.gov) -  Jul 14, 2022   
    P2,  N=40, Active, not recruiting, 
    This retrospective study suggests clinical effectiveness of lenvatinib monotherapy in a real-world setting among previously treated patients with uHCC, including among those previously treated with immunotherapy. Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Jul 2022 --> Jul 2023
  • ||||||||||  DC101 / Eli Lilly, H3B-6527 / Eisai
    Journal:  Combined inhibition of FGFR4 and VEGFR signaling enhances efficacy in FGF19 driven hepatocellular carcinoma. (Pubmed Central) -  Jul 13, 2022   
    Mechanistic studies showed that the combination resulted in enhanced efficacy through increased anti-angiogenic and anti-tumorigenic activities. Overall, our results indicate that this combination can be a highly effective treatment option for FGF19 driven HCC patients, and provide preclinical validation of a combination that can be readily tested in the clinical setting.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment change, IO biomarker:  NeoPele: A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma (clinicaltrials.gov) -  Jul 12, 2022   
    P2,  N=40, Active, not recruiting, 
    Overall, our results indicate that this combination can be a highly effective treatment option for FGF19 driven HCC patients, and provide preclinical validation of a combination that can be readily tested in the clinical setting. N=20 --> 40
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Jemperli (dostarlimab) / GSK
    Journal, Checkpoint inhibition, Mismatch repair, Tumor Mutational Burden, MSi-H Biomarker, IO biomarker:  Immune Checkpoint Inhibitors and Mismatch Repair Status in Advanced Endometrial Cancer: Elective Affinities. (Pubmed Central) -  Jul 11, 2022   
    However, several questions remain to be addressed, including the identification of patients who may benefit from the addition of ICIs as well as those who do not need immunotherapy. In the current paper, we provide an overview of the clinical development of immunotherapy in advanced or recurrent EC, discussing the role of MMR and the "elective affinities" between ICIs and this predictive biomarker in this setting.
  • ||||||||||  Journal:  Rapid Determination of 9 Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma in Human Plasma by QuEChERS-UPLC-MS/MS. (Pubmed Central) -  Jul 10, 2022   
    Lenvatinib, sorafenib, cabozantinib, apatinib, gefitinib, regorafenib, and anlotinib rendered good linearity over the range of 0.1-10 ng/ml, and 1-100 ng/ml for tivantinib and galunisertib...The method was deemed satisfactory with an accuracy of -7.34-6.64%, selectivity, matrix effect (ME) of 90.48-107.77%, recovery, and stability. The proposed method is simple, efficient, reliable, and applicable for the detection of TKIs in human plasma samples as well as for providing a reference for the clinical adjustment of drug administration regimen by monitoring the drug concentrations in the plasma of patients.